Drug Profile
Senexin
Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Biocad
- Class Antineoplastics
- Mechanism of Action Cyclin dependent kinase 19 inhibitors; Cyclin-dependent kinase 8 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Cancer in Russia